Pulmozyme Access Solutions provides reliable, effective access and reimbursement services to assist your patients and practice
Genentech is committed to helping all patients access Pulmozyme, regardless of their ability to pay
Pulmozyme Access Solutions offers a full range of access and reimbursement support for your patients and practice.
Find the right patient assistance program for your patients using the Patient Assistance Tool
To learn more about how Access Solutions can help, call 1-800-690-3023 to speak with one of the Access Solutions Specialists.
Is your patient insured?
Does your patient have commercial insurance?What does this mean?
Has your patient already been referred to a Genentech co-pay card and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible for assistance or no longer receiving it?
Is the patient using Pulmozyme for an indicated use?
Is the patient 18 years of age or older, or have a legal guardian over the age of 18?
Is the patient’s co-pay over $30 per month?
Pulmozyme Co-pay Card
This program may be able to help reduce your eligbile patients’ out-of-pocket expenses associated with their prescriptions.
Independent Co-pay Assistance Foundations
If patients need help with their medication co-pays, Pulmozyme Access Solutions can refer them to an independent co-pay assistance foundation supporting their disease state.
GATCF helps qualified patients receive their medicine free of charge. To qualify for free medicine from GATCF, patients need to meet specific criteria.
Resources for effective access and reimbursement services
Important Safety Information
Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product.
The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of ≥ 10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been observed and have been transient.
Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
The safety and effectiveness of Pulmozyme have been established in pediatric patients 5 years of age and older. The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 65 patients with cystic fibrosis aged 3 months to < 5 years. While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in pulmonary function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 98 pediatric patients with cystic fibrosis 3 months to 10 years of age (65 aged 3 months to < 5 years, 33 aged 5 to ≤ 10 years). The PARI BABY™ reusable nebulizer (which uses a facemask instead of a mouthpiece) was utilized in patients unable to demonstrate the ability to inhale or exhale orally throughout the entire treatment period (54/65, 83% of the younger; and 2/33, 6% of the older patients). Overall, the nature of adverse reactions was similar to that seen in the placebo-controlled trials in older patients. The number of patients reporting cough was higher in the younger age group as compared to the older age group (29/65, 45%; compared to 10/33, 30%) as was the number reporting moderate to severe cough (24/65, 37%; compared to 6/33, 18%). The number of patients reporting rhinitis was higher in the younger age group as compared to the older age group (23/65, 35%; compared to 9/33, 27%) as was the number reporting rash (4/65, 6% as compared to 0/33, 0%).